Med Biogenex Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
as on 13-12-2024
- Paid Up Capital ₹ 1.00 M
as on 13-12-2024
- Company Age 12 Year, 6 Months
- Last Filing with ROC 31 Mar 2024
- Satisfied Charges ₹ 1.00 M
as on 13-12-2024
- Revenue -28.30%
(FY 2020)
- Profit -22.04%
(FY 2020)
- Ebitda -4.31%
(FY 2020)
- Net Worth 35.46%
(FY 2020)
- Total Assets 5.60%
(FY 2020)
About Med Biogenex
The Company is engaged in the Consumer Goods Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 1.00 M.
The company has closed loans amounting to ₹1.00 M, and has no open charges as per Ministry of Corporate Affairs (MCA) records.
Bhola Nandi and Partha Shaw serve as directors at the Company.
- CIN/LLPIN
U74999WB2012PTC184011
- Company No.
184011
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
24 Jul 2012
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Kolkata
Industry
Company Details
- Location
Kolkata, West Bengal, India
- Telephone
- Email Address
- Website
- Social Media-
What products or services does Med Biogenex Private Limited offer?
Med Biogenex Private Limited offers a wide range of products and services, including Diabetes Medicine, Metformin Tablets.
Who are the key members and board of directors at Med Biogenex?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Bhola Nandi  | Director | 06-Dec-2019 | Current |
| Partha Shaw | Director | 02-Apr-2019 | Current |
Financial Performance of Med Biogenex.
Med Biogenex Private Limited, for the financial year ended 2020, experienced significant reduction in revenue, with a 28.3% decrease. The company also saw a substantial fall in profitability, with a 22.04% decrease in profit. The company's net worth Soared by an impressive increase of 35.46%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Med Biogenex?
In 2019, Med Biogenex had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
₹0
₹1.00 M
Charges Breakdown by Lending Institutions
- State Bank Of Bikaner & Jaipur : 0.10 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 28 Nov 2013 | State Bank Of Bikaner & Jaipur | ₹1.00 M | Satisfied |
How Many Employees Work at Med Biogenex?
Unlock and access historical data on people associated with Med Biogenex, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Med Biogenex, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Med Biogenex's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
